GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Many Bright Ideas Technologies Inc (TSXV:MBI.H) » Definitions » Cash And Cash Equivalents

Many Bright Ideas Technologies (TSXV:MBI.H) Cash And Cash Equivalents : C$0.00 Mil (As of Dec. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Many Bright Ideas Technologies Cash And Cash Equivalents?

Many Bright Ideas Technologies's quarterly cash and cash equivalents increased from Jun. 2024 (C$0.00 Mil) to Sep. 2024 (C$0.00 Mil) but then stayed the same from Sep. 2024 (C$0.00 Mil) to Dec. 2024 (C$0.00 Mil).

Many Bright Ideas Technologies's annual cash and cash equivalents increased from Dec. 2022 (C$0.00 Mil) to Dec. 2023 (C$0.00 Mil) but then stayed the same from Dec. 2023 (C$0.00 Mil) to Dec. 2024 (C$0.00 Mil).


Many Bright Ideas Technologies Cash And Cash Equivalents Historical Data

The historical data trend for Many Bright Ideas Technologies's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Many Bright Ideas Technologies Cash And Cash Equivalents Chart

Many Bright Ideas Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 0.01 - - -

Many Bright Ideas Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Many Bright Ideas Technologies Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Many Bright Ideas Technologies  (TSXV:MBI.H) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Many Bright Ideas Technologies Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Many Bright Ideas Technologies's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Many Bright Ideas Technologies Business Description

Traded in Other Exchanges
N/A
Address
598 East Kent Avenue South, Vancouver, BC, CAN, V5X 4V6
Many Bright Ideas Technologies Inc is a Canada-based life science company. It focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests. The company is engaged in managing the license and rights to GeneFx Lung, which is a proprietary gene expression-based test for identifying those patients with early-stage non-small-cell lung cancer.

Many Bright Ideas Technologies Headlines

No Headlines